%0 Journal Article
%A Habl, Gregor
%A Uhl, Matthias
%A Katayama, Sonja
%A Kessel, Kerstin A
%A Hatiboglu, Gencay
%A Hadaschik, Boris
%A Edler, Lutz
%A Tichy, Diana
%A Ellerbrock, Malte
%A Haberer, Thomas
%A Wolf, Maja B
%A Schlemmer, Heinz-Peter
%A Debus, Jürgen
%A Herfarth, Klaus
%T Acute Toxicity and Quality of Life in Patients With Prostate Cancer Treated With Protons or Carbon Ions in a Prospective Randomized Phase II Study-The IPI Trial.
%J International journal of radiation oncology, biology, physics
%V 95
%N 1
%@ 0360-3016
%C Amsterdam [u.a.]
%I Elsevier Science
%M DKFZ-2017-02065
%P 435 - 443
%D 2016
%X The purpose of this study was to compare safety and feasibility of proton therapy with that of carbon ion therapy in hypofractionated raster-scanned irradiation of the prostate, in a prospective randomized phase 2 trial.In this trial, 92 patients with localized prostate cancer were enrolled. Patients were randomized to receive either proton therapy (arm A) or carbon ion therapy (arm B) and treated with a total dose of 66 Gy(relative biological effectiveness [RBE]) administered in 20 fractions (single dose of 3.3 Gy[RBE]). Patients were stratified by the use of antihormone therapy. Primary endpoint was the combined assessment of safety and feasibility. Secondary endpoints were specific toxicities, prostate-specific antigen progression-free survival (PFS), overall survival (OS), and quality of life (QoL).Ninety-one patients completed therapy and have had a median follow-up of 22.3 months. Among acute genitourinary toxicities, grade 1 cystitis rates were 34.1
%K Androgen Antagonists (NLM Chemicals)
%K Prostate-Specific Antigen (NLM Chemicals)
%F PUB:(DE-HGF)16
%9 Journal Article
%$ pmid:27084659
%R 10.1016/j.ijrobp.2016.02.025
%U https://inrepo02.dkfz.de/record/125941